AEON Biopharma (AEON Biopharma) Inventory-to-Revenue : 0.00 (As of Mar. 2024)

---

AEON Biopharma Inventory-to-Revenue Chart

---

Competitive Comparison of AEON Biopharma's Inventory-to-Revenue

For the Biotechnology subindustry, AEON Biopharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

---

AEON Biopharma's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEON Biopharma's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where AEON Biopharma's Inventory-to-Revenue falls into.

---

AEON Biopharma Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AEON Biopharma's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

AEON Biopharma's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

AEON Biopharma  (AMEX:AEON) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AEON Biopharma's Days Inventory for the three months ended in Mar. 2024 is calculated as:

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

AEON Biopharma's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

---

AEON Biopharma Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of AEON Biopharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Total Inventories Revenue Days Inventory Cost of Goods Sold Inventory Turnover

---

AEON Biopharma (AEON Biopharma) Business Description

Executives

Strathspey Crown Holdings Group, Llc	10 percent owner	4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660
Priveterra Sponsor, Llc	10 percent owner	300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Daewoong Co., Ltd	10 percent owner	244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211
Alexander Blair Wilson	officer: Exec VP, CLO & Corp Secretary	5 PARK PLAZA, SUITE 1750, IRVINE CA 92614
Chad Oh	officer: Chief Medical Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Marc Forth	director, officer: Chief Executive Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660
Jost Fischer	director	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660
Oleg Grodnensky	10 percent owner	300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301
Vikram Malik	10 percent owner	17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614
Peter A Reynolds	officer: Chief Financial Officer	27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610
Robert J Palmisano	director, 10 percent owner	110 HARTWELL AVENUE, LEXINGTON MA 02173
Shelley B Thunen	director	C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric G Carter	director	C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Meredith	officer: Chief Legal Officer&Secretary	300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301